Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does not cover obesity medications in the United States, to purchase the drug at their local pharmacy for a discounted price of $499 per month.
This replaces the previous offer, which provided Wegovy to cash-paying patients for $650 per month. Patients enrolled in government-funded healthcare programs are not eligible for these savings. Meanwhile, those with commercial insurance that covers Wegovy may pay as little as $0 per month, with a maximum savings of $225 per 28-day supply.
Until this announcement, the $499-per-month offer…
